Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Bernstein Initiates Genmab(GMAB.US) With Hold Rating
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (JAZZ), Acadia Healthcare (ACHC) and Genmab (GMAB)
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
TD Cowen Maintains Genmab(GMAB.US) With Hold Rating
TD Cowen Reaffirms Their Hold Rating on Genmab (GMAB)
RBC Capital Keeps Their Buy Rating on Genmab A/S (0MGB)
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31